SAGE Therapeutics Inc FutureCast: An R&D and Portfolio Review Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : On zuranolone, in the real world, after the initial 2-week course of treatment and first follow-up, can you give us any quantitative metrics on how often a patient may need to see a psychiatrist per year versus a typical patient on traditional SSRI? And on 718, from a clinical trial logistics perspective, how reliable can the digit symbol substitution test for executive functioning be for patients with Parkinson's, for example, given the underlying impaired motor control in that condition?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Right. Yes. Just how reliable can DSST be for executive functioning given -- especially in Parkinson's given there's an underlying impairment of motor control there?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : First, another 1 on 718. How early in disease were patients in the PARADIGM and LUMINARY studies? I know LUMINARY was in MCI. But how important is it to get these patients earlier in disease to get maximal effect? Or should that not theoretically matter as much? And then just a quick second one on KINETIC 2 and 324. Why are you not using a 45-milligram dose in the Phase IIb? I think it's just the 15, 30 and 60. If patients were titrated down in the Phase II, I think it was the 45 milligram. So just review the down titration that you guys saw a bit more in the KINETIC study?